Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3831
| Predicate | Object |
|---|---|
| rdf:type | |
| rdfs:label |
Vectibix (Injection)
|
| dailymed-instance:activeIng... | |
| dailymed-instance:genericDr... | |
| dailymed-instance:boxedWarn... |
WARNING: DERMATOLOGIC TOXICITY and INFUSION REACTIONS: Dermatologic Toxicity: Dermatologic toxicities occurred in 89% of patients and were severe (NCI-CTC grade 3 and higher) in 12% of patients receiving Vectibix monotherapy. [see Dosage and Administration (2.1), Warnings and Precautions (5.1), and Adverse Reactions (6.1)]. Infusion Reactions: Severe infusion reactions occurred in approximately 1% of patients. [see Warnings and Precautions (5.2) and Adverse Reactions (6.1)]. Although not reported with Vectibix, fatal infusion reactions have occurred with other monoclonal antibody products. [see Dosage and Administration (2.1)].
|
| dailymed-instance:activeMoi... | |
| dailymed-instance:inactiveI... | |
| dailymed-instance:possibleD... | |
| dailymed-instance:genericMe... |
panitumumab
|
| dailymed-instance:fullName |
Vectibix (Injection)
|
| dailymed-instance:represent... | |
| dailymed-instance:routeOfAd... | |
| dailymed-instance:name |
Vectibix
|